Showing 691-700 of 5802 results for "".
Hydroquinone in 2021
https://practicaldermatology.com/topics/pigmentary-disorders/hydroquinone-in-2021/23592/A year after OTC hydroquinone was pulled from the market as part of the CARES Act, a dermatologist discusses the effects on patient care.Optimizing Absorption of Oral Isotretinoin
https://practicaldermatology.com/columns/clinical-focus-1/optimizing-absorption-of-oral-isotretinoin/23066/An update on lidose-isotretinoin and the ability to enhance absorption in the absence of high-fat meals.Advancing Sexual Health Histories in Dermatology: A Modernized Comprehensive Approach for Diverse Populations
https://practicaldermatology.com/topics/feature/advancing-sexual-health-histories-in-dermatology-a-modernized-comprehensive-approach-for-diverse-populations/28864/According to the CDC’s 2022 STI Surveillance Report, sexually transmitted infections (STIs) have seen a 1.9% increase in diagnoses over the past five years, underscoring a persistent public health challenge.DermWire TV Extra: 3-Year Clinical Data on Lebrikizumab
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-extra-3-year-clinical-data-lebrikizumab/28648/Study author Melinda Gooderham, MSc, MD, FRCPC, discusses the new three-year clinical data presented at the European Academy of Dermatology & Venereology (EADV) Congress on the efficacy and safety of lebrikizumab, which the FDA recently approved on September 13 for adults and adolescents with moNIH Analysis Examines Association Between AD and Comorbidities
https://practicaldermatology.com/programs/practical-dermatology-atopic-dermatitis/nih-analysis-examines-association-between-ad-and-comorbidities/27113/In this week's DermwireTV, new NIH data looks at the association between AD and several health conditions; a study evaluates the effect of lebrikizumab monotherapy in patients with moderate-to-severe AD over 16 weeks; and Andrew Mastro provides tips on how to optimize the first 5 minutes with a patiDermWireTV: International Launch of AviClear; Biological Effects of Air Pollution on Human Skin; New AAD Guidelines for Acne Care
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-international-launch-of-aviclear-biological-effects-of-air-pollution-on-human-skin-new-aad-guidelines-for-acne-care/20261/In this episode of DermWireTV, we report on the international launch of the first energy-based device FDA-cleared for the long-term treatment of mild, moderate, and severe acne. An expert discusses a recent study that examines the biological effects of air pollution on human skin equivalents. For thAmerican Academy of Dermatology Conference Takeaways: M&A and the Economy
https://practicaldermatology.com/conferences/aad-2023/american-academy-of-dermatology-conference-takeaways-mampa-and-the-economy/23906/Highlights from the 2023 American Academy of Dermatology annual meeting and survey of strategic buyers.Hyperpigmentation Treatment Pearls and More
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/hyperpigmentation-treatment-pearls-and-more/20161/Corey Hartman, MD shares his approach to treating periorbital hyperpigmentation in darker skin types, including using fillers to replace volume, give lift, and replace loss of bony structures and fat pads. Dr. Hartman also discusses the benefits of Cynosure’s PicoSure device to correct hyperpigmentaWhat to do if your practice’s social accounts are inactive
https://practicaldermatology.com/topics/practice-management/what-to-do-if-your-practices-social-accounts-are-inactive/20127/Social media is the can’t miss marketing platform of 2022. However, it has been around long enough that many businesses have already tried it and given up years ago. If you are among the many dermatology practices with an old, outdated, nearly inactive Facebook or other social accounts, check out thScientifically Speaking: Effective By Design with Josh Makower, MD
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-effective-by-design-with-josh-makower-md/20106/Josh Makower, MD has been at the forefront of several medical innovations. Listen in as he describes his approach and discusses his latest product with host Joel L. Cohen, MD. The Avéli device from Revelle Aesthetics is FDA-cleared to reduce cellulite in the buttocks and thighs temporarily.